Page 1 of 2

Montana Right-to-Try Request for Proposals (RFP)

The new SB 535 law in Montana (background) creates the first-ever scalable business model to administer therapies under right-to-try laws. We are a coalition of individuals & groups with connections in biotech, academia, venture capital and (local) medical clinics, looking to fund and assist partners seeking to enter Montana under SB 535 under the working title "Montana Longevity Coalition". About This Questionnaire This form has two parts: Part 1: Indicate Partner Interest Part 2: Request for Proposals You should fill out Part 1 if you: - Represent one or more of: Clinics, MDs, biotechs, manufacturers, CROs, pharma companies, individual professionals with a strong track record in your area of expertise. You should fill out Part 2 if you: - Have or are working on biopharma assets/IP and: - Aim to treat patients at scale using treatments that are not approved by the FDA, but are at a minimum proven to be safe and at best come with a high degree of scientific evidence of their efficacy (e.g. already approved in other countries like Japan, Europe etc.) - Have a focus broadly on longevity, regenerative, preventative or precision medicine - treatment of diseases or terminal illness is not necessarily in contrast, please apply anyway - Have interest in pursuing faster alternatives to the conventional drug development pathway, in alignment with the ideas around R2T of medical freedom. For example by working through US pathways like state R2T, compassionate use, or non-US jurisdictions Next Step Partners that are a fit with the program will be invited to take part in small circle info sessions on the details of how to enter Montana under SB 535. Data Privacy Statement Your privacy is important to us. The information you provide in this questionnaire will be used solely for the purpose of evaluating potential participation in the Montana Longevity Coalition and related research or business development activities. All responses will be treated as confidential and will only be accessible to authorized members of the coalition’s research and operations team. We will not share your personally identifiable information or proprietary business details with third parties without your explicit consent, except as required by law. Data may be aggregated and anonymized for reporting or analysis, but no individual or company will be identified in any public materials without prior written permission. By submitting this questionnaire, you acknowledge and consent to the collection and use of your information as described above. If you have any questions about how your data will be used or wish to request deletion of your information, please contact us at [email protected]

Part 1: Indicate Partner Interest

What is your name?

What is your email?

What is your organisation?

What is your title/role in the organization?

Where are you based?

Where is your organization's headquarters?

What does your organization do? Select all that apply.

What does your organization do? Select all that apply.

How much revenue does the business make annually?

How much revenue does the business make annually?
A
B
C
D
E
F
G

Does your organization provide services in the United States?

Does your organization provide services in the United States?
A
B
C

What would be the primary driver of interest to you in Montana? Select only one.

What would be the primary driver of interest to you in Montana? Select only one.
A
B
C
D
E

Please describe in more detail your interest in Montana.

Did you try using right-to-try, compassionate use or other regulatory fast-track programs in the United States? What was your experience?

Did you try taking advantage of non-US jurisdictions with favorable medical regulations? What was your experience?

Anything else we should know about your organisation?

Do you have treatments available (directly or indirectly) that you want to bring to Montana, if feasible and commercially viable to you?

Do you have treatments available (directly or indirectly) that you want to bring to Montana, if feasible and commercially viable to you?
A
B